Glasgow, Scotland, 30th January 2017: Mironid® Limited, a leader in cell signalling-directed drug discovery, is delighted to start the New Year by initiating a £606K programme to expand its repertoire of proprietary LoAc® molecules. The work will be 70% funded by the UK’s innovation agency,…
Aberdeen, United Kingdom, January 10, 2017 – SIRAKOSS Ltd., a UK-based medical device company developing innovative bone grafting solutions for the $3 billion global orthopaedic market, has announced that the United States Patent and Trademark Office (USPTO) has granted two patents for its bone graft…
Berlin, Germany, 09 January 2017 – Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, today announced the completion of its € 8.0 (approx. US$ 8.3) million Series A funding round. Epidarex Capital led the round, and Evotec AG participated together with a consortium of investors…
Mironid’s ShoLo® and LoAc® programmes benefit from a close association with Dr George Muller as a key medicinal chemistry and experienced drug development advisor. George was an Outstanding Investigator and Senior Director of Chemistry with Celgene until his retirement in mid-2011. George has a deep…